Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
301060 Shanghai Labway Clinical Laboratory
21.120
+0.180+0.86%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30
Assets
Current assets
Money funds
97.25% 372.62M -- 244.48M -14.59% 351.96M -- 348.18M
Transactional financial assets
-- 0 -- 338.68M 248.96% 420.93M -- 277.91M
Notes receivable and accounts receivable
180.14% 2.06B -- 1.27B 51.77% 819.61M -- 876.59M
-Notes receivable
-32.9% 20.05M -- 22.42M 4.42% 25.28M -- 20.16M
-Accounts receivable
189.19% 2.04B -- 1.25B 53.99% 794.33M -- 856.43M
Other receivables (including interest and dividends)
-42.43% 5.92M -- 9.11M -3.55% 7.89M -- 9.73M
-Other receivable
-42.43% 5.92M -- -- -3.55% 7.89M -- --
Advance payment
8.37% 37.88M -- 34.54M -5.71% 15.88M -- 30.51M
Inventories
32.73% 170.72M -- 199.21M -5.22% 139.44M -- 132.46M
Other current assets
125.07% 22.45M -- 14.49M 61.75% 11.35M -- 5.82M
Total current assets
89.53% 2.66B -- 2.11B 41.15% 1.77B -- 1.68B
Non Current assets
Other equity investment
-- 347.11K -- 347.11K -- -- -- --
Fixed assets
101.96% 242.79M -- -- 37.52% 161.41M -- --
Fixed assets liquidation
-- 0 -- -- -- 0 -- --
Constru in process
-- 5M -- -- -- 16.98M -- --
Construction materials
-- 0 -- -- -- 0 -- --
Intangible assets
1.06% 13.84M -- 14.05M 14.85% 14.81M -- 14.89M
Goodwill
0% 30.09M -- 30.09M 0% 30.09M -- 30.09M
Long deferred expense
54.44% 53.78M -- 51.27M -11.3% 32.05M -- 33.65M
Deferred tax assets
102.29% 24.82M -- 13.81M -4.82% 13.39M -- 13.71M
Usufruct assets
-1.06% 62.66M -- 58.92M -9.72% 62.72M -- 59.86M
Other non current assets
-69.61% 4.66M -- 8.97M -13.43% 6.97M -- 2.98M
Total non current assets
51.16% 437.98M -- 360.23M 17.47% 338.41M -- 302.61M
Total assets
82.98% 3.1B 53.59% 2.47B 36.72% 2.11B 39.47% 1.98B
Liabilities
Current liabilities
Short term loan
44719.78% 102.1M -- 2M -- 2M -- 2M
Notes payable and accounts payable
344.2% 591.36M -- 349.97M 101.87% 253.03M -- 161.6M
-Accounts payable
344.2% 591.36M -- 349.97M 101.87% 253.03M -- 161.6M
Contract liabilities
-55.9% 13.73M -- 10.4M -49.72% 9.28M -- 14.37M
Salaries payable
265.32% 157.74M -- 94.15M 100.17% 72.79M -- 42.41M
Taxs payable
227.68% 79.35M -- 61.82M 101.87% 39.3M -- 41.63M
Other payable (including interest and dividends)
113.91% 38.67M -- 19.33M 35.49% 21.89M -- 40.77M
-Interest payable
-- 0 -- -- -- 0 -- --
-Dividend payable
-0.8% 5.88M -- 5.88M -0.8% 5.88M -- 5.93M
-Other payable
169.88% 32.79M -- -- 56.5% 16.01M -- --
Non current liabilities due within one year
3.88% 15.76M -- 14.14M -4.18% 13.67M -- 15.19M
Other current liabilities
-12.36% 3.17M -- 1.17M -54.1% 1.01M -- --
Total current liabilities
272.8% 1B -- 552.98M 77.8% 412.98M -- 317.98M
Current liabilities
Bonds payable
-- 0 -- -- -- 0 -- --
Deferred tax liabilities
-- 4.91M -- -- -- -- -- --
Long term deferred income
-58.41% 2M -- 2.23M -56.6% 2.66M -- 4.8M
Lease liabilities
-0.74% 47.78M -- 45.74M -7.74% 50.03M -- 44.65M
Total non current liabilities
3.3% 54.69M -- 47.97M -12.69% 52.69M -- 49.45M
Exceptional items of total current liabilities
-- 0 -- 0 -- 0 -- 0
Total liabilities
228.45% 1.06B 104.89% 600.95M 59.14% 465.67M 83.61% 367.43M
Shareholders equity
Paid-in capital
13.64% 400.52M -- 400.52M 13.64% 400.52M -- 400.52M
Capital reserve funds
20.61% 557.01M -- 552.8M 19.7% 552.8M -- 552.8M
Surplus reserve funds
70.84% 37.82M -- 37.82M 70.84% 37.82M -- 22.14M
Retained profit
82.68% 884.19M -- 751.03M 48.72% 573.8M -- 562.99M
Shareholders equity without minority interests
42.34% 1.88B -- 1.74B 28.04% 1.56B -- 1.54B
Minority interests
210.68% 166.86M -- 129.58M 198.1% 74.88M -- 77.93M
Total shareholder equity
48.92% 2.05B 42.16% 1.87B 31.46% 1.64B 32.25% 1.62B
Total liabilityies and equity
82.98% 3.1B 53.59% 2.47B 36.72% 2.11B 39.47% 1.98B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
----Unqualified opinion--
Auditor
----Rongcheng Accounting firm (Special General Partnership)--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company is a high-tech enterprise that provides comprehensive health management solutions relying on medical laboratory and pathological diagnosis services. Through the business model of providing third-party medical diagnostic services and selling in vitro diagnostic products, the company enables medical technology laboratories such as hospital laboratory, pathology department and central laboratory to help them reduce operating costs and operational risks. improve the quality and technical level of medical services. At present, the company's business covers more than ten provinces and cities, and there are more than ten regional medical laboratory and pathological diagnosis centers, forming a brand, large-scale and standardized laboratory network. The company is an integrated service provider providing overall solutions for the inspection and diagnosis industry, providing third-party medical testing and pathological diagnosis services to medical institutions at all levels, selling in vitro diagnostic products of well-known brands at home and abroad and other professional technical support, in order to meet the differentiated needs of medical institutions at all levels. Medical laboratory and pathological diagnosis services, sales of in vitro diagnosis products, medical diagnosis services, etc. Corporate honors: top 100 Shanghai service enterprises in 2019, top 100 private service enterprises in Shanghai, civilized units in Shanghai, etc.
CEO: --
Market: --
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...